Here's Why Aehr Test Systems Stock Slumped in November

Aehr Test Systems shares fell 11.6% in November amid a broader pullback in AI-related stocks but remain up about 52% year-to-date, reflecting investor interest in its AI-focused WLBI test systems. While legacy WLBI demand for SiC EV chips has pressured revenue in recent years, management reported new orders and said “multiple leading companies” requested benchmark evaluations for AI processors since the early-October earnings call, signaling strengthening AI end markets that could partially offset automotive weakness.

Analysis

Market structure: AI-driven capex is bifurcating winners — semiconductor test-equipment suppliers (AEHR, TER) and hyperscalers who outsource benchmarking capture most upside; legacy EV SiC WLBI demand is softer, pressuring pure-play EV test suppliers. Pricing power will be concentrated where benchmarking/qualification is scarce (hyperscaler engagements), suggesting 10–30% higher ASPs for short-run AI test services versus commodity EV WLBI. Cross-asset: a tech risk-on tied to AI orders would steepen yields (10–30 bps on 2s10s in a strong cycle), tighten IG spreads, raise implied vol in single-name options (20–50%+ realized volatility for small caps), and support USD strength into tech rallies.

Risk assessment: primary tail risks are a hyperscaler capex pullback (20–40% budget cut) and export controls on AI accelerators that could wipe short-term addressable market for AEHR; operational risks include component shortages or a large order cancellation. Time horizons: days — sentiment swings ±10–20% on NVDA headlines; weeks — order-backslog visibility in earnings; 3–12 months — revenue recognition and capacity expansion consequences. Hidden dependencies: AEHR’s upside is binary and concentrated in a few customers (single-customer risk >30% of reorder flow).

Trade implications: direct plays — size positions to conviction: small-cap AEHR exposure should be 2–3% of risk capital, TER 1–2% as earlier-cycle leverage. Use pair trades: long TER / short small-cap AI momentum names to capture lead-lag; implement 3–6 month call spreads on TER and 6–12 month protective puts on AEHR. Portfolio: overweight semiconductor capital equipment by +2–4% and trim EV/SiC suppliers by -2–3% until WLBI demand stabilizes.

Contrarian angles: consensus underestimates order concentration and the binary nature of AEHR’s revenue — the market may be underpricing cancellation risk even as it prices AI upside. The November pullback (c.11.6%) may be an overreaction if two consecutive quarters show AI revenue growth >20% QoQ; conversely, if NVDA or hyperscalers guide down, equipment cyclicals could rout 30–50% fast. Historical parallel: 2017 AI capex spikes showed rapid upside then hard mean reversion once capacity saturated — plan exits around 30–40% targets or on order reversals.

Key Decisions for Investors

• Establish a 2–3% portfolio long position in AEHR (AEHR) only upon a confirmatory catalyst: either (A) next quarterly report shows AI-related revenue growth >=20% QoQ or (B) company announces multiple hyperscaler order wins within 90 days; set a hard stop-loss at -20% and take-profit at +40% within 6–12 months.
• Initiate a 1–2% long position in Teradyne (TER) or buy a 3–6 month call spread sized to 1% of capital to capture earlier-cycle AI test equipment demand; target 20–40% upside in 6–12 months and use a 15% stop-loss on the stock leg.
• If holding AEHR, sell 1–3 month covered calls to harvest premium during sentiment rallies; alternatively buy 6–12 month protective puts 20% OTM sized 0.5–1% if the stock rallies >25% from current levels to hedge binary order risk.
• Reallocate +2–4% weight into semiconductor capital equipment (TER, KLAC alternatives) and reduce EV/SiC supplier exposure by -2–3% until two successive quarters show WLBI order stabilization; monitor NVDA earnings and hyperscaler capex guidance over the next 30 days as primary catalysts.